A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Zepbound is a prescription weight loss drug manufactured by Eli Lilly. Users inject themselves with doses weekly. The active ingredient in Zepbound is tirzepatide. It mimics the hormones glucagon ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
In the current Lexaria Study, the oral DehydraTECH-tirzepatide was conservatively dosed at only 56 times more tirzepatide than what is administered via an injected Zepbound® dose, meaning that a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback